Results 31 to 40 of about 692,269 (276)

Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens

Saudi Pharmaceutical Journal, 2023
Cancer cells often depend on multiple pathways for their growth and survival, resulting in therapeutic resistance and the limited effectiveness of treatments.
Ali M. Alaseem
doaj   +1 more source

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

Cellular & Molecular Biology Letters, 2021
Since the discovery of the first MDM2 inhibitors, we have gained deeper insights into the cellular roles of MDM2 and p53. In this review, we focus on MDM2 inhibitors that bind to the p53-binding domain of MDM2 and aim to disrupt the binding of MDM2 to ...
Lucia Haronikova, Ondrej Bonczek, Pavlina Zatloukalova, Filip Kokas-Zavadil, Martina Kucerikova, Philip J. Coates, Robin Fahraeus, Borivoj Vojtesek   +7 more
doaj   +1 more source

MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation

Biomedicines, 2023
Inhibition of the interaction between MDM2 and p53 has emerged as a promising strategy for combating cancer, including the treatment of glioblastoma (GBM).
Karolina I. Pellot Ortiz, Julian S. Rechberger, Leo F. Nonnenbroich, David J. Daniels, Jann N. Sarkaria   +4 more
doaj   +1 more source

Dual Targeting of MDM4 and FTH1 by MMRi71 for Induced Protein Degradation and p53-Independent Apoptosis in Leukemia Cells

Molecules, 2022
MDM2 and MDM4 are cancer drug targets validated in multiple models for p53-based cancer therapies. The RING domains of MDM2 and non-p53-binder MDM2 splice isoforms form RING domain heterodimer polyubiquitin E3 ligases with MDM4, which regulate p53 ...
Rati Lama, Samuel L. Galster, Chao Xu, Luke W. Davison, Sherry R. Chemler, Xinjiang Wang   +5 more
doaj   +1 more source

MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer

Frontiers in Oncology, 2021
With the adoption of inhibitors of cyclin dependent kinases 4 and 6 (CDK4/6i) in combination with endocrine therapy as standard of care for the treatment of advanced and metastatic estrogen receptor positive (ER+) breast cancer, the search is now on for ...
Neil Portman, Neil Portman, Julia Chen, Julia Chen, Elgene Lim, Elgene Lim   +5 more
doaj   +1 more source

MAGE-A cancer/testis antigens inhibit MDM2 ubiquitylation function and promote increased levels of MDM4 [PDF]

, 2015
Melanoma antigen A (MAGE-A) proteins comprise a structurally and biochemically similar sub-family of Cancer/Testis antigens that are expressed in many cancer types and are thought to contribute actively to malignancy.
Susan E. Bray (264528), Thompson, Alastair M., Hourihan John, Quinlan Philip R., Philip R. Quinlan (743773), Thompson Alastair M., Meek, David W., Alastair M. Thompson (743775), Meek, David W, Marcar Lynnette, Lee B. Jordan (743774), Ihrig Bianca, David W Meek, Ted R. Hupp (141798), Hupp Ted R., Ihrig, Bianca, Hourihan, John, Meek David W., Bray Susan E., Thompson, Alastair M, Quinlan, Philip R., Susan E Bray, Lynnette Marcar (743770), Hupp, Ted R., John Hourihan, Philip R Quinlan, Jordan, Lee B., Bray, Susan E, Ted R Hupp, Lynnette Marcar, Quinlan, Philip R, David W. Meek (743776), Jordan Lee B., Alastair M Thompson, Marcar, Lynnette, Bianca Ihrig, John Hourihan (743772), Hupp, Ted R, Bray, Susan E., Lee B Jordan, Bianca Ihrig (743771), Jordan, Lee B   +41 more
core   +2 more sources

The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a. [PDF]

, 2014
p53 and its major E3 ligase Mdm2 are both ubiquitinated and targeted to the proteasome for degradation. Despite the importance of this in regulating the p53 pathway, little is known about the mechanisms of proteasomal recognition of ubiquitinated p53 and
J Das, S Menendez, Menendez, S., Saville, M. K., S Dayal, Das, J., M K Saville, Dayal, S., A Sparks, Robertson, P., P Robertson, Sparks, A.   +11 more
core   +1 more source

MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy

Frontiers in Oncology, 2021
Inhibition of the MDM2/X-p53 interaction is recognized as a potential anti-cancer strategy, including the treatment of glioblastoma (GB). In response to cellular stressors, such as DNA damage, the tumor suppression protein p53 is activated and responds ...
Xanthene Miles, Charlot Vandevoorde, Alistair Hunter, Julie Bolcaen   +3 more
doaj   +1 more source

MDM2 negatively regulates the human telomerase RNA gene promoter [PDF]

, 2005
<b>Background:</b> We have previously demonstrated that NF-Y and Sp1 interact with the human telomerase RNA (hTR) promoter and play a central role in its regulation. We have also shown that pRB activates the hTR promoter, but the mechanism
Jiangqin Zhao (6471), Keith, W.N., Katrina Jackson (6473), Bilsland, A., Jackson, K., Keith W Nicol, Alan Bilsland (6472), Zhao, J., Zhao Jiangqin, Bilsland Alan, Jackson Katrina, W. Nicol Keith (261494), Alan Bilsland, Katrina Jackson, Jiangqin Zhao, W Nicol Keith   +15 more
core   +2 more sources

Inhibition of the MDM2/p53 Interaction Design, Synthesis and Evaluation of MDM2 Inhibitors [PDF]

, 2014
Numerous essential cellular processes are regulated by protein-protein interactions (PPIs) and PPIs have therefore been recognised as potential new drug targets. The transcription factor p53 is often referred to as the guardian of the genome due to its
Pettersson, Mariell, Grøtli, Morten,, Bliman, David,, Pettersson, Mariell,, Bood, Mattias,   +4 more
core   +1 more source